NEW YORK – Despite recording $1 billion in revenues for the first time in its history, Quidel on Thursday also reported a hiccup in its plans to submit an over-the-counter viral antigen test for regulatory authorization. The firm provided details on two anticipated product launches as well.
On a conference call reviewing its fourth quarter and full-year 2020 financial results, company executives also admonished investors to ignore unfounded M&A rumors.